Comprehensive health protection: Modern cervical cancer screening solutions

Cervical cancer is a concern for many women, but did you know, this is one of the most preventable and curable cancers if detected early.

Here, we offer advanced, trend-setting cervical cancer screening solutions for your lab.

Why is cervical cancer screening important?

Cervical cancer usually develops silently, with no obvious symptoms in the early stages. By the time there are manifestations, the disease is usually in a severe stage, treatment will be more difficult and expensive.

Periodic screening is the "golden key"

• Early detection: Helps identify abnormal changes in cervical cells, even before they turn into cancer.
• Increased chances of successful treatment: When detected at a pre-cancerous or very early stage, the cure rate can be as high as 90% or more.

Advanced Screening Solutions

HPV-DNA/Co-test with cytology

It is a modern, automated, molecular biology test that directly detects the presence of DNA of the Human Papillomavirus (HPV) virus – the main cause of more than 99% of cervical cancer cases.

The test is approved by the world's leading health organizations (including the US FDA and the European Community). This is the only test currently approved by the FDA for all 3 screening options:

• Primary screening
• Co-testing with cytology testing
• Supplementation after cytology test with ASC-US results

This test is capable of:

• Detected 14 high-risk HPV strains (Hr-HPV)
• Separately, 02 strains of HPV with the highest risk are HPV 16 and HPV 18, which are the cause of about 70% of cervical cancer cases.
• At the same time, the presence of 12 other high-risk HPV types (including 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) was determined.

Superior Accuracy: With a sensitivity of up to 90-95%, it can detect the presence of high-risk HPV virus even if there are no obvious cellular changes.

Proven long-term safety: up to 3 years of safety on file.

Advanced testing quality control technology

• No risk of cross-reactivity with HPV even if it is low: The HPV DNA test is FDA approved without requiring a risk of cross-reactivity disclosure.
• Proprietary technology is included in each reaction to reduce false positives.
• Intracellular control of β-globin to prevent false-negative results.